Adamas Announces New Employment Inducement Grant
March 10 2017 - 4:34PM
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the
compensation committee of the company’s board of directors granted
a new employee a stock option to purchase 26,250 shares of the
company’s common stock, at a per share exercise price of $16.97,
the closing trading price on March 7, 2017, and restricted stock
units to acquire 4,375 shares of the company’s common stock. The
stock option and restricted stock units vest over four years and
were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016
Inducement Plan, which was approved by the company's board of
directors in March 2016 under Rule 5653(c)(4) of the Nasdaq Global
Market for equity grants to induce new employees to enter into
employment with the company.
About Adamas Pharmaceuticals,
Inc.Adamas develops new medicines to improve the daily
lives of those affected by chronic neurologic disorders, including
Parkinson’s disease, multiple sclerosis, epilepsy and Alzheimer’s
disease. Adamas has pioneered a platform to develop medicines,
called chrono-synchronous therapies, for chronic neurologic
disorders based on an understanding of the time-dependent biologic
processes responsible for disease activity and drug response to
potentially achieve symptomatic relief without tolerability issues.
The company’s most advanced product candidate, ADS-5102, is in
development for levodopa-induced dyskinesia (LID) in patients with
Parkinson’s disease and walking impairment. An NDA supporting
ADS-5102 for the treatment of LID in patients with Parkinson’s
disease is under review by the FDA, with a PDUFA date of August 24,
2017. Adamas is exploring other indications for ADS-5102 for
further development. Adamas is also investigating ADS-4101 for the
treatment of partial onset seizures in patients with epilepsy.
Additionally, Adamas’ licensed assets, NAMENDA XR® and NAMZARIC®,
are currently marketed by Allergan, and Adamas is eligible to
receive royalties on sales of these medicines beginning in June
2018 and May 2020, respectively. For more information, please visit
www.adamaspharma.com.
NAMENDA XR® and NAMZARIC® are trademarks of Merz
Pharma GmbH & Co. KGaA.
Martin Forrest
Vice President, Corporate Communications & Investor Relations
Adamas Pharmaceuticals, Inc.
510-450-3528
ir@adamaspharma.com
Adamas Pharmaceuticals (NASDAQ:ADMS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Adamas Pharmaceuticals (NASDAQ:ADMS)
Historical Stock Chart
From Sep 2023 to Sep 2024